Navigation Links
Hormone that controls iron levels may be target for atherosclerosis treatment
Date:11/16/2011

Researchers at Emory University School of Medicine have identified hepcidin, a hormone that regulates iron levels in the body, as a potential target for treating atherosclerosis.

Suppressing hepcidin is a way to reduce the iron levels inside the white blood cells found in arterial plaques. Reducing iron levels pushes those cells to clean up harmful cholesterol in a process called "reverse cholesterol transport," interfering with atherosclerosis, researchers have found.

The data is being presented Wednesday, Nov. 16 by Aloke Finn, MD, assistant professor of medicine (cardiology) and colleague Omar Saeed at the American Heart Association Scientific Sessions meeting in Orlando. Charles Hong, MD, PhD, from Vanderbilt University and collaborators from CVPath Institute contributed to the research.

When mice modeling atherosclerosis are given a compound that reduces hepcidin levels, they have smaller atherosclerotic plaques and less fat in their plaques, as well as reduced foam cell formation. Foam cells are white blood cells that accumulate cholesterol and are signs of atherosclerosis, which can lead eventually to heart attacks and strokes.

The compound LDN 193189 reduces hepcidin levels by blocking its production. LDN 193189 is also being investigated as a treatment for inflammatory bowel disease and for anemia related to critical illness.

Finn is also presenting research on how hemoglobin, the iron-containing protein that allows red blood cells to carry oxygen, affects macrophages.

Finn and his colleagues used isolated human cells and a rabbit model of atherosclerosis to show that macrophages respond to hemoglobin by increasing production of proteins that transport cholesterol and pump iron out.

In the context of atherosclerosis, iron is toxic because it amplifies the action of reactive oxygen species, leading to more inflammation and more foam cells. Previous research has shown that hemorrhage within atherosclerotic plaques, leading to the release of hemoglobin from red blood cells, is linked to enlargement of the plaque's necrotic core a sign of "vulnerable plaque."

"We were led to the hepcidin research by our work on macrophages," Finn says. "We discovered a different type of macrophages that detoxify iron. They take it up and spit it out again with an iron transport protein."

"Hemorrhage is bad, but as bad at it is, these macrophages seem to protect against the toxic effects of iron. Giving macrophages hemoglobin encourages them to behave in this detox mode," he says.


'/>"/>

Contact: Jennifer Johnson
404-727-5696
Emory University
Source:Eurekalert

Related medicine news :

1. Radiation Plus Hormone Therapy Extends Life in High-Risk Prostate Cancer
2. Radiation plus hormone therapy greatly improves survival
3. Hormone in birth control shot linked to memory loss
4. Obese people regain weight after dieting due to hormones
5. Hunger Hormones May Drive Post-Dieting Weight Gain
6. Research involving thyroid hormone lays foundation for more targeted drug development
7. Breast Cancer Risk May Rise With High Hormone Levels
8. Elevated hormone levels add up to increased breast cancer risk
9. Breast tenderness in women getting combo hormone therapy associated with increase in breast density
10. Shift Workers Show Rise in Stress Hormone
11. Is Female Hormone Disorder Tied to Familial Heart Risk?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... , ... Hidden Cypress in Sun City is the place to be on March 3rd to ... Weniger will be hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting ... pricing on offers. In addition, prizes will be given away and light refreshments will be ...
(Date:2/13/2016)... ... February 13, 2016 , ... The producers of Enterprises TV are ... The increasingly modern world of instantaneous consumption proves very convenient for businesses. With new ... oil and coal, which pollutes our air, water, and soil. It can also threaten ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi , a ... Providers list for its expertise in eClinical Solutions. DDi has built its solution ... technology needs of global clients. DDi provides smarter technology for Clinical Development, Regulatory ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... members of South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on ...
(Date:2/12/2016)... California (PRWEB) , ... February 12, 2016 , ... Coco ... their participation in Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will ... way to stay hydrated before the big event. The invitation-only gifting suite, held this ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016  Eli Lilly and Company (NYSE: ... the Alimta® (pemetrexed disodium) vitamin regimen patent would not presently ... France , Italy ... the product only with dextrose solution.  ... UK Court of Appeal held that Lilly,s patent would be ...
(Date:2/12/2016)... 12 2016  OMS Supply, a large provider of ... announced today the recent launching of their new company ... of features that enhance the user experience and enable ... --> --> Despite ... company that started in early 2016, they have already ...
(Date:2/12/2016)... LOUISVILLE, Ky. , Feb. 12, 2016 ... it has completed a $47.1 million Series ... investors Cormorant Asset Management, Hillhouse Capital Group ... investors Morningside Venture Investments, AJU IB Investment, ... will be used to further advance clinical ...
Breaking Medicine Technology: